MAPT and Alzheimer disease: We assessed differences and overlaps with healthy control subjects (A − T −) and full-blown AD patients (A + T +) in terms of disease burden measured as CSF p-tau/Aβ42 [2, 14] and cerebral glucose hypometabolism, evaluated with fluorodeoxyglucose-positron emission tomography (FDG-PET), whose specific topographical patterns have achieved an increasingly supportive role in the diagnostic algorithm of AD [15–17].